Reuters logo
BRIEF-Cynata Therapeutics receives advice from US FDA regarding Cymerus MSC products
July 5, 2017 / 1:35 AM / 3 months ago

BRIEF-Cynata Therapeutics receives advice from US FDA regarding Cymerus MSC products

July 5 (Reuters) - Cynata Therapeutics Ltd

* Received written advice from US FDA regarding regulatory approval path for Cynata’s proprietary cymerus™ mesenchymal stem cell (MSC) products Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below